Literature DB >> 30926527

Characterization and evaluation of different mesoporous silica kinds as carriers for the development of effective oral dosage forms of glibenclamide.

Paola Mura1, Maurizio Valleri2, Elisa Fabianelli3, Francesca Maestrelli2, Marzia Cirri3.   

Abstract

This work evaluated the suitability of various mesoporous silicas as carriers for developing an oral formulation endowed with improved dissolution properties of glibenclamide, hypoglycemic agent poorly water-soluble. The different silicas were examined for solid-state, morphology, and technological and physical-chemical properties (granulometry, specific surface area, wettability, water content, water activity, apparent density, flowability, compactability). A pairwise comparison allowed a ranking, by importance order, of the parameters examined and, for each parameter, a score was assigned to each silica type. Data statistical treatment (JMP software) indicated Neusilin®US2 and Syloid®XDP3150 as the best materials. Different loading methods were tested: physical mixing; addition of drug dissolved in a volatile solvent, subsequently evaporated; addition of drug dissolved in a solvent. Methods involving drug dissolution enabled drug amorphization and intimate dispersion within the silica porous structure. Dissolution tests indicated Syloid®XDP3150 as the most effective silica in enhancing drug dissolution properties, providing a release rate clearly faster than from commercial tablets. Drug amorphization, improved wettability, increased surface area of the drug, finely dispersed into the highly porous silica, were the main factors responsible for this finding. Moreover, the obtained results suggested that drug dissolution rate can be properly tuned, based on the suited choice of the silica type.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aerosil®200, Aerosil®300, Aeroperl®300 (CAS 12 945-52-5); Glibenclamide; Glibenclamide (CAS 10238-21-8); Improved dissolution; Mesoporous silica; Nanomaterials; Neusilin®US2 (CAS 12511-31-8); Pairwise comparison; Parteck® SLC (CAS 7631-86-9); Rxcipients®GL200 (CAS 112926-00-8); Statistical classification; Syloid®244FP and Syloid®XDP3150 (CAS 7631-86-9); Zeopharm®600 (CAS 1344-95-2)

Mesh:

Substances:

Year:  2019        PMID: 30926527     DOI: 10.1016/j.ijpharm.2019.03.049

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats.

Authors:  Reham I Amer; Ghada E Yassin; Reem A Mohamed; Ahmed M Fayez
Journal:  AAPS PharmSciTech       Date:  2021-07-13       Impact factor: 3.246

2.  Tablets of "Hydrochlorothiazide in Cyclodextrin in Nanoclay": A New Nanohybrid System with Enhanced Dissolution Properties.

Authors:  Francesca Maestrelli; Marzia Cirri; Fátima García-Villén; Ana Borrego-Sánchez; César Viseras Iborra; Paola Mura
Journal:  Pharmaceutics       Date:  2020-01-28       Impact factor: 6.321

3.  Design and Characterization of Phosphatidylcholine-Based Solid Dispersions of Aprepitant for Enhanced Solubility and Dissolution.

Authors:  Sooho Yeo; Jieun An; Changhee Park; Dohyun Kim; Jaehwi Lee
Journal:  Pharmaceutics       Date:  2020-04-29       Impact factor: 6.321

4.  Evaluation of Hydrophilic and Hydrophobic Silica Particles on the Release Kinetics of Essential Oil Pickering Emulsions.

Authors:  Zhe Li; Xiaoxia Jiang; Hongning Liu; Ziheng Yao; Ao Liu; Liangshan Ming
Journal:  ACS Omega       Date:  2022-03-01

Review 5.  Mesoporous Silica Particles as Drug Delivery Systems-The State of the Art in Loading Methods and the Recent Progress in Analytical Techniques for Monitoring These Processes.

Authors:  Katarzyna Trzeciak; Agata Chotera-Ouda; Irena I Bak-Sypien; Marek J Potrzebowski
Journal:  Pharmaceutics       Date:  2021-06-24       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.